Skip to content
DataLookout
Menu

RenaissanceNCT05076682

Reverse Triple Negative Immune Resistant Breast Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
    • Enrollment increased: 80 → 90 participants
    • Interventions modified
    • Trial arms changed: 8 → 9
    • Secondary endpoints: details revised at 1 of 6 entries
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 3 words
  2. Minor Enrollment target: 70 to 80
    • Interventions: AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium… to AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium…
    • Study arms: 7 to 8
    • Study description expanded, about 2 words
    v6
  3. Notable Enrollment target: 30 to 70v5 Show 7 more changesShow less
    • Primary completion date: Dec 2022 to Dec 31, 2026
    • Eligibility criteria expanded, about 13 words
    • Study completion date: Mar 2023 to Mar 31, 2027
    • Interventions: Choline (Drug), Efavirenz (Drug), Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug) to AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium…
    • Secondary endpoints: details revised at 2 of 6 entries
    • Study description shortened, about 83 words
    • Study arms: 3 to 7
  4. Notable Enrollment target: 20 to 30v4 Show 4 more changesShow less
    • Interventions: Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug), choline (Drug) to Choline (Drug), Efavirenz (Drug), Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug)
    • Secondary endpoints: 4 to 6
    • Study description expanded, about 46 words
    • Study arms: 2 to 3
  5. Minor Start date changed from estimate of Apr 2022 to Jun 30, 2022v3
  6. Notable Start date: Oct 15, 2021 to Apr 2022v2 Show 6 more changesShow less
    • Primary endpoints: 1 to 2
    • Primary completion date: Oct 15, 2022 to Dec 2022
    • Study completion date: Dec 31, 2022 to Mar 2023
    • Interventions: PD-1 inhibitor and chemo (Drug), Sodium Cromoglicate (Drug), choline (Drug) to Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug), choline (Drug)
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 1 word
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Immune changes in peripheral blood
Timeframe: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

Secondary (6)

Disease Control Rate (DCR)
Progression Free Survival (PFS)
Safety and treatment-related AEs
Biomarker analysis1
Biomarker analysis2
Show 1 moreShow less
Biomarker analysis3

Arms and interventions

CholineExperimental

Choline with anti-PD-1 immunotherapy

Sodium cromoglicateExperimental

Sodium cromoglicate with anti-PD-1 immunotherapy

EfavirenzExperimental

Efavirenz with anti-PD-1 immunotherapy

HER2 lowExperimental

HER2 low expression

HER2 0Experimental

HER2 0 expression

AK131Experimental

AK131(CD73/PD1 bispecific antibody)

MecapegfilgrastimExperimental

Mecapegfilgrastim with anti-PD-1 immunotherapy

TheophyllineExperimental

Theophylline with anti-PD-1 immunotherapy

MifepristoneExperimental

Mifepristone with anti-PD-1 immunotherapy

Drugs: Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline, Mifepristone

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, China